Sign in

CIK 0001664710

  • Non-accelerated filer
  • Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
811173868
Phone
+1 617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$17,830
in 3 filings, $18K under 10b5-1 plans

Net −$17,830. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Prener Anne −$12K Director sold 8% of stake
  2. Newton Charles W. −$6K Director sold 5% of stake
Date Insider Transaction Shares Price Value Owned after
2025-11-21 ORBIMED ADVISORS LLC Director Returned to the company −140,057 $17.75 $2.5M 759,155
2025-11-21 ORBIMED ADVISORS LLC Director Returned to the company −74,465 $17.75 $1.3M 45,057
2024-08-13 ORBIMED ADVISORS LLC Director Sale −220,600 $44.01 $9.7M 899,212
2024-08-13 ORBIMED ADVISORS LLC Director Sale −29,400 $44.01 $1.3M 119,522
2020-04-13 ORBIMED ADVISORS LLC Director Conversion +744,612 744,612
2020-04-13 ORBIMED ADVISORS LLC Director Conversion +148,922 148,922
2020-04-13 ORBIMED ADVISORS LLC Director Purchase +375,200 $16.00 $6.0M 1,119,812
2020-04-13 ORBIMED ADVISORS LLC Director Conversion · Series C Preferred Stock −744,612 0
2020-04-13 ORBIMED ADVISORS LLC Director Conversion · Series C Preferred Stock −148,922 0

Page 1 of 1 · 9 trades